1. Home
  2. RCEL vs GLSI Comparison

RCEL vs GLSI Comparison

Compare RCEL & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • GLSI
  • Stock Information
  • Founded
  • RCEL N/A
  • GLSI 2006
  • Country
  • RCEL United States
  • GLSI United States
  • Employees
  • RCEL N/A
  • GLSI N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • GLSI Biotechnology: Pharmaceutical Preparations
  • Sector
  • RCEL Health Care
  • GLSI Health Care
  • Exchange
  • RCEL Nasdaq
  • GLSI Nasdaq
  • Market Cap
  • RCEL 161.5M
  • GLSI 133.4M
  • IPO Year
  • RCEL N/A
  • GLSI 2020
  • Fundamental
  • Price
  • RCEL $5.32
  • GLSI $9.15
  • Analyst Decision
  • RCEL Strong Buy
  • GLSI Strong Buy
  • Analyst Count
  • RCEL 4
  • GLSI 1
  • Target Price
  • RCEL $16.50
  • GLSI $39.00
  • AVG Volume (30 Days)
  • RCEL 326.4K
  • GLSI 37.8K
  • Earning Date
  • RCEL 08-07-2025
  • GLSI 08-13-2025
  • Dividend Yield
  • RCEL N/A
  • GLSI N/A
  • EPS Growth
  • RCEL N/A
  • GLSI N/A
  • EPS
  • RCEL N/A
  • GLSI N/A
  • Revenue
  • RCEL $71,661,000.00
  • GLSI N/A
  • Revenue This Year
  • RCEL $57.16
  • GLSI N/A
  • Revenue Next Year
  • RCEL $36.69
  • GLSI N/A
  • P/E Ratio
  • RCEL N/A
  • GLSI N/A
  • Revenue Growth
  • RCEL 41.35
  • GLSI N/A
  • 52 Week Low
  • RCEL $4.71
  • GLSI $8.06
  • 52 Week High
  • RCEL $14.16
  • GLSI $18.15
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 39.85
  • GLSI 42.26
  • Support Level
  • RCEL $4.71
  • GLSI $8.67
  • Resistance Level
  • RCEL $5.55
  • GLSI $9.37
  • Average True Range (ATR)
  • RCEL 0.29
  • GLSI 0.28
  • MACD
  • RCEL 0.08
  • GLSI 0.00
  • Stochastic Oscillator
  • RCEL 41.03
  • GLSI 28.74

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: